Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

mRNA-based COVID-19 vaccines are effective against Indian SARS-CoV-2 variant, says study

A team of scientists recently conducted a study to examine whether natural infection-induced or vaccine-induced neutralizing antibodies are capable of eliminating the risk of recently emerged Indian variant (B.1.617.1) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 May 2021

Case study examines prescriptions and healthcare use in non-hospitalized COVID-19 recoverers

In a new study published in The Lancet, a team of researchers examined prescription drug and healthcare use after SARS-CoV-2 infection in those who did not require hospital admission.

12 May 2021

Long and short-range risk of airborne transmission of SARS-CoV-2

In a recent research study, Florian Poydenot et al. performed a quantitative assessment of indoor and outdoor transmission risk; and how to reduce the contributions of public spaces to the propagation of SARS-CoV-2. The study is published on the medRxiv, a preprint server for health sciences.

12 May 2021

Study confirms rare blood clotting risk linked to ChAdOx1-S vaccine - benefits still outweigh risks

New research published in BMJ confirmed evidence of blood clotting finding a small risk after receiving one Oxford-AstraZeneca ChAdOx1-S severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.

12 May 2021

Spread of minority SARS-CoV-2 variants in New York City

Viruses mutate to survive. But not all mutations are beneficial to the virus. On the other hand, some mutations such as N501Y and E484K on the spike protein propelled specific severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants to ‘variant of concern’ status, due to their ability to increase transmission and weaken the response of neutralizing antibodies.

12 May 2021

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

The emergence of this variant highlighted the uneven pace of mutation and selection of variants. New bioinformatics tools are the need of the hour to clarify this and confirm a dynamic evolution by tracking the mutation rates of the spike protein. It generally takes 1 – 6 months for current variants causing COVID-19 case peaks and deaths to survive the pressure of selection.

11 May 2021

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

A new study released as a bioRxiv* preprint tried to establish how tissues such as the upper respiratory tract (URT) – which harbor the virus and often act as the point of entry – are difficult to access for routine testing, but are responsive to vaccination.

11 May 2021

Study reveals acute immunologic changes in children with long COVID

Many reports are beginning to emerge on the ‘long COVID’ phenomenon. But a new study, released as a preprint on the medRxiv* server, describes, for the first time, immunologic changes observed in children with PASC.

11 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Researchers have designed a new class of TMPRSS2 inhibitors that have shown broad antiviral activity against coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 May 2021

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

Now, a new report describes a case of a coincidental mRNA vaccination and SARS-CoV-2 infection in a 31-year-old doctor, addressing the theoretical considerations for potential risks and further required actions in case more cases appear in the future.

11 May 2021

SARS-CoV-2 UK variant more infectious because of higher viral load

The coronavirus disease 2019 (COVID-19) pandemic was triggered by the uncontrolled spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A year and a half later, the relationship between SARS-CoV-2 viral load and infectiousness remains a matter of scientific debate. Now, a new preprint research paper posted to the bioRxiv server aims to quantify this relationship

11 May 2021

Severe COVID-19 linked to genetic clotting predisposition

Thus, the need to stratify the risk of severe or critical disease in patients presenting with SARS-CoV-2 infection remains a crying necessity. A new preprint research paper posted to the medRxiv server discusses the relationship between severe disease and pre-existing susceptibility to clots and other diseases of the cardiovascular system.

11 May 2021

The travel-related origin and spread of SARS-CoV-2 B.1.620 strain

A new preprint research paper posted to the medRxiv* server describes a new variant B.1.620, which appeared in Lithuania, and is now prevalent in several countries in Europe, as well as in central Africa.

11 May 2021

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age.

10 May 2021

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

Researchers from the US recently determined the sensitivity of the Quidel Sofia SARS Antigen FIA test (Sofia 2). They found a high viral load specimen that tested negative repeatedly while using this antigen test. The study is published on the preprint server, medRxiv.

10 May 2021

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers in The Netherlands have warned that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces complex reprogramming of innate immune responses that should be considered in the development and use of mRNA-based vaccines.

10 May 2021

Researchers show SARS-CoV-2 genes can be integrated into the human genome

Researchers in the United States have shown that genes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – can be integrated into the genome of infected human cells.

10 May 2021

Study identifies most persistent neurological problems during long COVID-19

Neuropsychiatric issues have been frequently reported in coronavirus disease 2019 (COVID-19) long-haulers. A new study on the medRxiv* preprint server has found which neurological symptoms are likely to persist after a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

10 May 2021

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.

10 May 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

mRNA-based COVID-19 vaccines are effective against Indian SARS-CoV-2 variant, says study

Case study examines prescriptions and healthcare use in non-hospitalized COVID-19 recoverers

Long and short-range risk of airborne transmission of SARS-CoV-2

Study confirms rare blood clotting risk linked to ChAdOx1-S vaccine - benefits still outweigh risks

Spread of minority SARS-CoV-2 variants in New York City

Evolutionary-spreading model predicts another devastating COVID-19 peak around July 2021

T cell populations in nasal mucosa expand after COVID-19 mRNA vaccination

Study reveals acute immunologic changes in children with long COVID

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

SARS-CoV-2 UK variant more infectious because of higher viral load

Severe COVID-19 linked to genetic clotting predisposition

The travel-related origin and spread of SARS-CoV-2 B.1.620 strain

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

Lab reports 1st instance of SARS-CoV-2 variants affecting antigen test performance

Research suggests Pfizer-BioNTech COVID-19 vaccine reprograms innate immune responses

Researchers show SARS-CoV-2 genes can be integrated into the human genome

Study identifies most persistent neurological problems during long COVID-19

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in